Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: up, up and away

November 25, 2019 6:54pm

I am NOT selling optimism; it might be time to go to the mattresses; cover your six (portfolio), SELL into strength

News: The U.S. FDA approved Oxbryta a drug for sickle cell anemia from Global Blood Therapeutics (GBT +$3.89) to treat adults and pediatric patients aged 12 years or older. The treatment is the first to target the underlying cause of the disease rather than symptoms. The drug, known as voxelotor, works by preventing red blood cells from sickling, a deformation that restricts flow of oxygen in blood vessels, leading to severe pain and organ damage

Pre-open indications: 7 HITs including BUYs and SELLs into strength

In the short run, values can be pretty senseless if one side or the other decides to be aggressive in their buying or selling.

Framing the main takeaway … pricing, volume and machine trading creates volatility and liquidity!

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Monday the IBB closed up +2.84% while the XBI closed up +3.75%
Friday the IBB closed up +1.11% while the XBI closed up +0.51%

The advance/decline line scenario of 45 covered companies:

Monday the close was positive with an A/D line of 34/8, 0 flat, 1 reversed merged (HSGX) and 2 acquired;

Friday the close was positive with an A/D line of 27/14, 1 flat, 1 reversed merged (HSGX) and 2 acquired;

Henry’omics:

Sector equities and indexes rose on Monday as the market’s rally to record highs resumed amid increasing expectations that China and the U.S. will reach a so-called phase one trade deal.

Monday’s gains come after the market’s rally took a pause last week, with the S&P 500 snapping a six-week winning streak. The Dow fell for the first week in five while the NASDAQ ended a seven-week run.

Equities have had a banner year but, “our” universe of cell and gene therapy companies have been stymied by alternating sentiment driven by trading … NOT investment.

The S&P 500 is up 25% in 2019, and is headed for its biggest one-year gain since 2013. Historically, the S&P 500 has carried over its momentum into the following year when rallying at least 25% in year. The NASDAQ, has rallied 30.1% year to date, on pace for its best yearly performance in six years. The Dow is up 20.3% year to date <CNBC>.

I'm NOT the tusting "sort" when it comes to share pricing; check your entry prices, cut your risk positions and build your cash position - there are BUYs and SELLs to be considered toward the end of December to prepare for the New Year!

Decliners:

ReNeuron (RENE.L -$9.00 after Friday’s +$+$1.50, Wednesday’s -$4.00, Tuesday’s -$2.50 and last Monday’s +$11.50);
Voyager therapeutics (VTGR -$0.31);
Solid Biosciences (SLDB -$0.21);
MiMedx (MDXG -$0.17);
BioLife Solutions (BLFS -$0.16);

Incliners:

Alnylam Pharmaceuticals (ALNY +$5.51 after Friday’s -$4.29, Thursday’s +$2.99 after Wednesday’s +$7.34, Tuesday’s +$5.20 and last Monday’s +$0.68);
Global Blood Therapeutics (GBT +$3.89);
CRISPR Therapeutics (CRSP +$3.47 after Friday’s +$2.81, Thursday’s -$8.03 after an offering was proposed);
Regenxbio (RGNX +$3.11 after Friday’s +$0.71);
Sage therapeutics (SAGE +$3.05 after Friday’s -$2.78);

The percentage (%) indicators:

Monday’s range of the 34 upside was +0.01% (CLBS) to +11.58% (EDIT) while the 8 downside ranged from -0.03% (ONCE) to -6.79% (RENE.L);

Friday’s range of the 27 upside was +0.23% (CLLS) to +24.75% (VSTM +$0.22) while the 14 downside ranged from -0.05% (ONCE) to -4.35% (BSTG);

Upside volume stats: to compare

• Monday: 12 out of the 34 upside had higher than the 3 month average volume;

Friday: 8 out of the 27 upside had higher than the 3 month average volume;

Downside volume stats:

Monday: 7 out of the 8 downside had higher than the 3 month average volume;
Friday: 6 out of the 14 downside had higher than the 3 month average volume;

0 flat with 1 reverse merged (HSGX), 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche could be soon according to rumors from FTC by year’s end.

November’s sessions:

Monday closed POSITIVE with 8 decliners, 34 advancers, 0 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 14 decliners, 27 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed NEGATIVE with 21 decliners, 19 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed POSITIVE with 18 decliners, 23 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 7 decliners, 34 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 22 decliners, 18 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 13 decliners, 26 advancers, 3 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed NEGATIVE with 25 decliners, 17 advancers, 0 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed NEGATIVE with 29 decliners, 12 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed NEGATIVE with 29 decliners, 12 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGAIVE with 27 decliners, 14 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 11 decliners, 29 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed POSITIVE with 18 decliners, 21 advancers, 3 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed NEGATIVE with 27 decliners, 13 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 17 decliners, 23 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with19 decliners, 22 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 7 decliners, 33 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

10 hours 54 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.